Medimmune Llc

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This study tests whether adding new cancer drugs to standard chemotherapy and bevacizumab can better control metastatic microsatellite-stable colorectal cancer. About 61 adults with this advanced cancer will receive different treatment combinations. The goal is to find safer, mor…

This early-stage trial tests two new drug combinations in people with advanced EGFR-mutated non-small cell lung cancer whose previous treatments have stopped working. The study combines a biologic (oleclumab) with either the targeted drug osimertinib or another experimental drug …

This phase 2b trial tests whether the immunotherapy drug tremelimumab can help people with advanced mesothelioma live longer. About 571 patients who have already tried standard chemotherapy will receive either tremelimumab or a placebo. The main goal is to see if the drug improve…